CV Sciences (CVSI) Non-Current Deferred Tax Liability (2013 - 2026)
CV Sciences (CVSI) reported Non-Current Deferred Tax Liability of $7000.0 for Q1 2026, up 75.0% on a YoY basis from $4000.0 in Q1 2025, and little changed sequentially from $7000.0 in Q4 2025.
CV Sciences (CVSI) Non-Current Deferred Tax Liability (2013 - 2026) Analysis & Trends
CV Sciences (CVSI) has 13 years of Non-Current Deferred Tax Liability data on file, last reported at $7000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deferred Tax Liability rose 75.0% year-over-year to $7000.0; the trailing twelve-month figure through Mar 2026 stood at $7000.0 (up 75.0% YoY), and the FY2025 full-year result was $7000.0, down 83.33% from the prior year.
- Non-Current Deferred Tax Liability was little changed at $7000.0 in Q1 2026, from $7000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $240000.0 in Q4 2022 to a low of $4000.0 in Q1 2025.
- A 5-year average of $42705.9 and a median of $19000.0 in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- Across the five-year window, Non-Current Deferred Tax Liability soared 287.1% in 2022 and plunged 83.33% in 2025, its largest moves.
- Tracing CVSI's Non-Current Deferred Tax Liability over 5 years: stood at $240000.0 in 2022, then slumped by 40.83% to $142000.0 in 2023, then tumbled by 70.42% to $42000.0 in 2024, then sank by 83.33% to $7000.0 in 2025, then changed by 0.0% to $7000.0 in 2026.
- Business Quant data shows CVSI's Non-Current Deferred Tax Liability at $7000.0 in Q1 2026, $7000.0 in Q4 2025, and $4000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,000.00 |
| Mar 31, 2026 | 7,000.00 |
| Dec 31, 2025 | 7,000.00 |
| Dec 31, 2025 | 7,000.00 |
| Sep 30, 2025 | 4,000.00 |
| Sep 30, 2025 | 4,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | 42,000.00 |
| Dec 31, 2024 | 42,000.00 |
| Sep 30, 2024 | 19,000.00 |
| Sep 30, 2024 | 19,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Mar 31, 2024 | 19,000.00 |
| Mar 31, 2024 | 19,000.00 |
| Dec 31, 2023 | 142,000.00 |
| Dec 31, 2023 | 142,000.00 |